Surgery Websites
LiverSource »  Faculty »  Medical Oncology »  R. Kate Kelley, M.D.
R. Kate Kelley, M.D.

R. Kate Kelley, M.D.

  • Health Sciences Professor of Clinical Medicine,
  • Division of Hematology Oncology
  • Department of Medicine

Contact Information

(415) 353-9888 (appts)
(415) 353-9959 (fax)
1600 Divisadero St.,MZ Bldg A 
San Francisco, CA 94143-1770
[email protected]
Open Popup

Biography

Dr. Robin Kate Kelley is a gastrointestinal oncologist who specializes in cancers arising from the liver, including hepatocellular carcinoma, bile duct cancer (cholangiocarcinoma), and gallbladder carcinoma. Her research interests include developing clinical trials of new treatments and combination therapies for these cancers, including immunotherapy approaches as well as translational research to identify molecular and genetic biomarkers of response. Dr. Kelley graduated from the David Geffen School of Medicine at UCLA and completed a residency at UCLA, where she was chief resident in internal medicine. She then completed a fellowship in hematology and oncology at UCSF.

Dr. Kelley received an American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium Merit Award in 2009, an ASCO Young Investigator Award in 2010, and the National Cancer Institute Cancer Clinical Investigator Team Leadership Award in 2014. She has authored numerous publications about treatments for advanced liver and bile duct cancers. She is involved in many organizations dedicated to improving the outcomes for patients with primary liver cancers, including National Comprehensive Cancer Network (NCCN) guideline panel for Liver Cancers, the National Cancer Institute Hepatobiliary Cancer Task Force, the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board, and the International Liver Cancer Association Education Committee.

Education & Training

  Institution  
  Degree    
  Dept or School    
  End Date    
  • University of California San Francisco, San Francisco, CA
  • Fellowship
  • Hematology/Oncology
  • 10/2009
  • University of California Los Angeles, Los Angeles, CA
  • M.D.
  • School of Medicine
  • 05/2002
  • Harvard College, Boston, MA
  • A.B.
  • Biochemical Sciences
  • 05/1997
  • University of California Los Angeles, Los Angeles, CA
  • Chief Residency
  • Internal Medicine
  • 06/2006
  • University of California Los Angeles, Los Angeles, CA
  • Residency
  • Internal Medicine
  • 05/2005

    • Residencies

    • UCLA, Intern, 2002-05, Medicine
    • UCLA, Resident, 2005-06, Medicine

    Fellowships

    • UCSF, Fellow, 2006-09, Hematology/Oncology

    Board Certifications

    • American Board of Internal Medicine
    • American Board of Internal Medicine: Medical Oncology - Subspecialty

    Program Affiliations

    • UCSF Helen Diller Family Comprehensive Cancer Center

    Clinical Expertise

    • Colon Cancer
    • Hepatocellular Carcinoma (Liver Cancer)
    • Liver Metastases
    • Pancreatic Cancer
    • Rectal Cancer
    • Stomach Cancer

    Research Interests

    • Anal Cancer
    • Colorectal Cancer
    • Hepatocellular Carcinoma (Liver Cancer)
    • Liver Metastases
    • Molecular Markers in Solid Tumors
    • Rectal Cancer

    Website Links

    Clinical Trials

    Data provided by UCSF Profiles, powered by CTSI

    Publications

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 118
    Data provided by UCSF Profiles, powered by CTSI
    1. Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgué A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol. 2023 Sep 06. View in PubMed
    2. Xie E, Yeo YH, Scheiner B, Zhang Y, Hiraoka A, Tantai X, Fessas P, de Castro T, D'Alessio A, Fulgenzi CAM, Xu S, Tsai HM, Kambhampati S, Wang W, Keenan BP, Gao X, Xing Z, Pinter M, Lin YJ, Guo Z, Vogel A, Tanaka T, Kuo HY, Kelley RK, Kudo M, Yang JD, Pinato DJ, Ji F. Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. JAMA Oncol. 2023 Oct 01; 9(10):1423-1431. View in PubMed
    3. Song X, Kelley RK, Green M, Standifer N, Lim K, Zhou D, Dunyak J, Negro A, Kurland JF, Ren S, Khan AA, Gibbs M, Abou-Alfa GK. Modeling of Proliferating CD4 and CD8 T-Cell Changes to Tremelimumab Exposure in Patients with Unresectable Hepatocellular Carcinoma. Clin Pharmacol Ther. 2023 10; 114(4):874-882. View in PubMed
    4. Spencer K, Pappas L, Baiev I, Maurer J, Bocobo AG, Zhang K, Jain A, De Armas AD, Reyes S, Le TM, Rahma OE, Stanton J, DeLeon TT, Roth M, Peters MLB, Zhu AX, Lennerz JK, Iafrate AJ, Boyhen K, VanCott C, Roberts LR, Lindsey S, Horick N, Goff LW, Mody K, Borad MJ, Shroff RT, Kelley RK, Javle MM, Goyal L. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma. J Natl Cancer Inst. 2023 07 06; 115(7):870-880. View in PubMed
    5. Budhu A, Pehrsson EC, He A, Goyal L, Kelley RK, Dang H, Xie C, Monge C, Tandon M, Ma L, Revsine M, Kuhlman L, Zhang K, Baiev I, Lamm R, Patel K, Kleiner DE, Hewitt SM, Tran B, Shetty J, Wu X, Zhao Y, Shen TW, Choudhari S, Kriga Y, Ylaya K, Warner AC, Edmondson EF, Forgues M, Greten TF, Wang XW. Tumor biology and immune infiltration define primary liver cancer subsets linked to overall survival after immunotherapy. Cell Rep Med. 2023 06 20; 4(6):101052. View in PubMed
    6. View All Publications

     

     
    Site Directory
      X